Search the site

Genome-wide association study of IgG1 responses to the choline-binding protein PspC of Streptococcus pneumoniae

Delayed development of antibodies to S. pneumoniae in infancy is associated with the development of atopy and asthma.

Lower anti-echovirus antibody responses in children presenting to hospital with asthma exacerbations.

This article assesses the absolute and specific antibody titres to VP1 antigens of the gut-trophic enteroviruses, echovirus 30 and Sabin 1 poliovirus, in...

Hypersensitivity: Immunological

This comprehensive review provides an introduction to immunological hypersensitivity, discusses the sensitisation of T-cell lineages.

Analysis of IgE binding patterns to house dust mite allergens in scabies-endemic communities: insights for both diseases

This study analysed the IgE binding patterns caused by house dust mite allergens in scabies endemic communities in Australia.

WHO/IUIS Allergen Nomenclature: Providing a common language

Aim was to standardize the names given to the antigens (allergens) that caused IgE-mediated allergies in humans

International consensus (ICON) on: Clinical consequences of mite hypersensitivity, a global problem

The objectives of this document are to highlight aspects of mite biology that are clinically relevant and to update the current knowledge on mite allergens

Hierarchy and molecular properties of house dust mite allergens

The allergenic load of house dust mite allergy is largely constituted by a few proteins with a hierarchical pattern of allergenicity.

Prominent IgE-binding and cytokine-inducing capacities of a newly cloned N-terminal region of Der f 14, an apolipophorin-like house dust mite allergen

The aims of this study were to clone the cDNA of Der f 14 corresponding to M-177 and to elucidate the allergenic capacities of the Der f 14-N.

T-cell responses against rhinovirus species A and C in asthmatic and healthy children

Infections by RV species A and C are the most common causes of exacerbations of asthma and a major cause of exacerbations of other respiratory disease.

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.